207 related articles for article (PubMed ID: 29317963)
1. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
[TBL] [Abstract][Full Text] [Related]
2. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.
Minami S; Ihara S; Kim SH; Yamamoto S; Komuta K
World J Oncol; 2018 Feb; 9(1):13-20. PubMed ID: 29581811
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
6. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
[TBL] [Abstract][Full Text] [Related]
7. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy.
Minami S; Ihara S; Komuta K
J Clin Med Res; 2018 Aug; 10(8):657-664. PubMed ID: 29977424
[TBL] [Abstract][Full Text] [Related]
9. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
[TBL] [Abstract][Full Text] [Related]
10. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Chang YC; Lin MC
PLoS One; 2015; 10(8):e0136252. PubMed ID: 26313661
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
[TBL] [Abstract][Full Text] [Related]
12. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Nishimatsu K; Komuta K
World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
Yun NK; Rouhani SJ; Bestvina CM; Ritz EM; Gilmore BA; Tarhoni I; Borgia JA; Batus M; Bonomi PD; Fidler MJ
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804721
[TBL] [Abstract][Full Text] [Related]
14. High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.
Zhao X; Zhang N; Zhang H; Liu P; Ma J; Hu C; Liu X; Hou T
Medicine (Baltimore); 2020 Nov; 99(46):e23150. PubMed ID: 33181687
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI.
Phan TT; Ho TT; Nguyen HT; Nguyen HT; Tran TB; Nguyen ST
Int J Gen Med; 2018; 11():423-430. PubMed ID: 30510441
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).
Mandaliya H; Jones M; Oldmeadow C; Nordman II
Transl Lung Cancer Res; 2019 Dec; 8(6):886-894. PubMed ID: 32010567
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Sim SH; Beom SH; Ahn YO; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Thorac Cancer; 2016 Mar; 7(2):161-6. PubMed ID: 27042217
[TBL] [Abstract][Full Text] [Related]
20. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
